ReviewCureus2025
Impact of Glucagon-Like Peptide-1 Agonists on Hepatocellular Carcinoma Risk and Management in Type 2 Diabetes Mellitus: A Scoping Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (T2DM) is a global health burden associated with an increased risk of severe complications, including hepatocellular carcinoma (HCC). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have gained prominence in the management of T2DM due to their glucose-lowering and weight-reduction effects. Emerging evidence further suggests that GLP-1RAs may mitigate liver-related conditions such as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, both of which are major risk factors for HCC development. This scoping review aimed to summarize and map the existing evidence on the impact of GLP-1RA therapy on the risk and management of HCC in adults with T2DM. A comprehensive, systematized search was conducted across EMBASE, Ovid MEDLINE, and Web of Science using terms related to "GLP-1 receptor agonists," "type 2 diabetes mellitus," and "hepatocellular carcinoma." Eligible studies included adult populations (≥18 years) with T2DM prescribed GLP-1RAs and reported outcomes specific to HCC incidence or progression. Six studies met the inclusion criteria, and most demonstrated a significantly reduced risk of HCC among patients with T2DM treated with GLP-1RAs compared with those using insulin or sulfonylureas. GLP-1RA monotherapy was generally more protective than combination therapy with insulin, whereas comparisons with metformin were inconclusive. The observed reduction in HCC risk is likely attributable to the anti-inflammatory, metabolic, and immunomodulatory effects of GLP-1RAs. Current evidence suggests that GLP-1RAs may play a protective role in reducing HCC risk among individuals with T2DM, particularly when compared with insulin-based regimens. Further longitudinal and randomized controlled trials are needed to elucidate the causal mechanisms and quantify the potential role of GLP-1RAs in reducing hepatocarcinogenesis. To our knowledge, this is the first scoping review to systematically map the literature examining GLP-1RA use and HCC risk in populations with T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.